Global Dual Chamber Syringe (DCS) Filling Machine Market - 2020-2027
発行: DataM Intelligence
世界のデュアルチャンバーシリンジ (DCS) 充填機の市場規模は、2020～2027年に7.8%のCAGRで成長すると見込まれています。市場成長の主な要因として、従来型のDCSから最新へのDCSへの移行や、アイソレーターやRABSなどの無菌製造環境の整備、バイオ医薬品産業での投資拡大などが挙げられます。現在は新型コロナウイルス感染症 (COVID-19) の感染拡大の影響で市況は停滞状態にありますが、COVID-19向けワクチンの生産体制が整えば、すぐに活況に転じると期待されています。
当レポートでは、世界のデュアルチャンバーシリンジ (DCS) 向け充填器の市場について分析し、市場の基本構造および最新情勢、全体的な市場動向の見通し (今後8年間分)、種類別・用途別および地域別の詳細動向、主な市場促進・抑制要因、市場競争構造、主要企業のプロファイル・事業戦略などについて調査しております。
The global dual chamber syringe (DCS) filling Machine market size was worth US$ XX billion in 2018 and is estimated to reach US$ XX billion by 2027, growing at a CAGR of 7.8 % during the forecast period (2020-2027).
Dual chamber syringe (DCS) filling machine is a device used for filling double chamber syringes. The DCS machines are designed for filling dual chamber prefilled syringes with a combination of drugs which can either be liquid or powder. These machines are majorly used by industrial pharmacy and hospital pharmacy.
The global dual chamber syringe filling machine market growth is majorly driven by the increasing technological advancements in filling machines. The increasing adoption of the newer dual-chamber technologies over the traditional dual-chamber syringe enhances the reliability, usability, and performance of the products. The introduction of isolators and restricted access barrier systems (RABS) creates a sterile manufacturing environment which can effectively separate the human operators from the fill-finish process. Several major device manufacturers in the fill-finish manufacturing are innovating new barrier isolation systems, that are integrated fill-finish machines which can carry out all stages of fill-finish processes. On the other hand, the traditional equipment used in fill-finish operations is of high cost and time-consuming, which makes the entire process complex and prone to contamination. The conventional stainless steel systems in traditional filling machines require additional cleaning and sterilization (CIP/SIP), whereas a single-use system eliminates the complex steps of sterilization and considerably reduces the change-over-time by simplifying end-of-batch breakdown and decontamination operations. For instance, DARA Pharmaceutical Packaging has introduced a dual-chamber syringes filling machine. Hence, owing to these factors, several biopharmaceutical companies are adopting these machines in drug production facilities.
In addition, the growing biopharmaceutical industry and rising investments by prefilled syringe manufacturers are also expected to drive the growth of the market during the forecast period. For instance, Nipro Corporation invested USD 14 million in its Germany and Japan plant to expand the production capacity of prefilled syringes. The company is also developing dual chamber prefilled syringes for treating patients with prostate cancer and breast cancer. Also, in October 2019, Credence MedSystems, an innovator in injectable drug delivery technology for the biopharmaceutical industry, was awarded a grant from the Bill & Melinda Gates Foundation to support the development of Credence's Dual Chamber Reconstitution Syringe tailored for use in developing nations. Hence, these type of development are expected to create opportunities for dual chamber syringe filling machine manufacturers in the coming years.
However, the high cost of the new technological systems such as isolators and Restricted Access Barrier System (RABS) is hampering the growth of the dual chamber syringe filling machine market. Restricted Access Barrier System (RABS) and isolators are well-equipped with advanced features which increases its price as compared to traditional systems. On average, isolators and RABS costs between US$ 4 million to US$ 8.0 million, which is five times that of traditional systems. Due to this, the accessibility is highly blocked for small pharma companies and research institutes that have a low budget for purchasing such equipment. Hence, the adoption of isolators and RABS is very low as compared to traditional systems in underdeveloped or developing countries, including China and India.
The COVID 19 pandemic has impacted several industries worldwide, which is expected to slow down economy till 2021. The lockdown has disrupted the pharmaceutical supply chain is expected to have implications in the near future. However, the pharmaceutical industry is getting ready up to fight COVID-19, with rapid development for new drugs and vaccines. In May 2020, Evonik announced to invest US$ 27 Mn to increase its active pharmaceutical ingredients production capacity at its Rosenheim and Hanau sites in Germany which are expected to complete by 2021, with further expansion planned by 2024.
The global dual chamber syringe filling machines are segmented into manual, semi-automatic, and automatic. Among these, the automatic segment is expected to gain maximum share during the forecast period indual chamber syringe (DCS) filling machine market. The increasing demand for automatic filling machines by large-scale production companies is leading to the growth of this segment. The automatic filling machines have lower human involvement, which decreases the chances of drug contamination, hence are highly adopted. The automatic filling machines is mostly used for commercial drugs.
On the basis of applications, the market is classified into hospital pharmacy, industrial pharmacy, and others. The industry pharmacy is dominating the dual chamber syringe filling machine market in 2019, as it involves high production, research, packaging, quality control, and sales of pharmaceutical products. The dual chamber syringe helps in the delivery of two drugs to ease the use it is provided with lyophilized injectable drug products. The pharmaceutical industry always prefers to adopt convenient products to patients for self-administration. Traditional systems are still widely used in small pharma and biopharma companies, R&D laboratories, and academic institutes.
North America dual chamber syringe filling machine held the largest market share in 2019, owing to technological developments in the syringe filling machines, a rising number of chronic diseases which leads to more demand for prefilled syringes. According to the hepatitis B foundation, more than 80,000 Americans are infected with Hepatitis B annually, and around 2 million Americans are chronically infected. Most of the manufacturers are getting approval for prefilled syringes for Hepatitis B vaccines in this region. For instance, Dynavax was one of the major pharma company to receive FDA approval for their prefilled syringe vaccine HEPLISAV-B in March 2018. The prefilled syringes play an important role in the administration of the vaccine in the US as there are rising demand for COVID-19 vaccine over the forecast period. There has seen significant developments in the syringe filling machines which also drives the growth of the market in this region. For instance, NC-based Mission Health in Asheville installed two RIV automated IV compounding systems from ARxIUM that sterile-fill liquids and lyophilized products into IV syringes, and bags for administration to Mission Health patients. Also, there are developments, such as a Universal Robots UR-3 robotic arm to provide syringe filling and handling, vial filling and handling, mark and verify, track-and-trace, unique device identification (UDI) which further boosts the growth of the market.
On the other hand, the Asia-Pacific dual chamber syringe (DCS) filling machine market is estimated to grow at the highest CAGR during the forecast period, owing to increased health awareness in developing countries, growing demand for syringe filling machines, and significant medical device manufacturing capacity.
The Dual Chamber Syringe (DCS) Filling Machine market is moderately competitive with a few major players. Some of the key players which are contributing to the growth of the market are DARA Pharmaceutical, Syntegon Technology, Prosys Servo Filling Systems, TurboFil Packaging Machines, among others. In 2019, Bosch sold one of its subsidiaries, Bosch Packaging Technology, to CVC Capital Partners and was renamed as Syntegon Technology. The company is a leading manufacturer of the product in several industries such as pharma, biopharma & fine chemicals, medical devices & diagnostics, food & confectionery, and other industries.
The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the Dual Chamber Syringe (DCS) Filling Machine market globally. For instance, in January 2019, NJM, a ProMach product brand, introduced the Dara NFL/2-RDL aseptic filling and closing machine for ready-to-use vials utilizing the RayDyLyo cap at Interphex booth.
The global dual chamber syringe (DCS) filling machine market report would provide an access to an approx. 53 market data table, 42 figures and 250 pages.
LIST NOT EXHAUSTIVE